Core Insights - The latest version of the medical insurance drug list will be implemented on January 1, 2026, with significant updates aimed at improving access to essential medications for insured individuals [1]. Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [2]. - New drugs include treatments for critical conditions such as triple-negative breast cancer and pancreatic cancer, as well as medications for chronic diseases and rare diseases [2]. Group 2: Expanded Payment Coverage - The payment scope has been broadened for 65 drugs, with new indications included for reimbursement, such as additional targets for non-small cell lung cancer treatments and expanded age eligibility for certain rare disease medications [3]. - Adjustments have been made to align payment criteria more closely with clinical practices, such as changing the payment range for certain drugs from "previous chemotherapy" to "past chemotherapy" [3]. - Some drugs have had restrictions removed or modified, while ensuring that reimbursement is still aligned with clinical guidelines [3]. Group 3: Drug Removal and Transition Policies - A total of 29 drugs have been removed from the list, primarily those that have been clinically obsolete or not produced for an extended period [4]. - A transition policy has been established for drugs that were removed but had not successfully renewed their contracts, allowing a 6-month period for insured individuals to purchase these drugs at the original reimbursement standards [4].

Core Points - The new "Chongqing Drug Directory (2025)" has been officially implemented since January 1, 2025, which includes 3,253 drugs in the National Drug Directory and additional local supplements [1] - The updated medical insurance directory has added 114 new drugs with an average price reduction of over 60%, significantly alleviating the financial burden on patients [2] - The new insurance directory for commercial health insurance has included 19 innovative drugs, enhancing treatment options for patients with various conditions [7] Group 1: National Drug Directory Changes - The National Drug Directory (2025) includes 3,253 drugs and 892 traditional Chinese medicine pieces, with Chongqing adding 201 traditional Chinese medicine pieces and 87 medical institution preparations [1] - The average price reduction for newly added drugs is over 60%, benefiting patients with conditions such as cancer and chronic diseases [2] - Specific examples include the price drop of the targeted drug for lung cancer from 12,900 yuan to 4,000 yuan per box [2] Group 2: Chronic Disease Treatment - The new directory has expanded the coverage of 65 drugs, including new indications for existing treatments, such as the inclusion of new targets for non-small cell lung cancer [4] - The price of the drug for Crohn's disease has been reduced from 22,045.02 yuan to 8,130.49 yuan for the intravenous form [3] - The expanded reimbursement range allows for more personalized treatment plans for early-stage breast cancer patients [4] Group 3: Commercial Health Insurance Innovations - The "Commercial Health Insurance Innovative Drug Directory (2025)" includes 19 new drugs, such as targeted therapies for various cancers and CAR-T products for blood cancers [7] - The directory serves as a reference for insurance companies, potentially increasing patient enrollment in commercial health insurance [7] - A new multi-layered medical insurance settlement platform has been launched to streamline the claims process for patients [8]

Core Viewpoint - The implementation of the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" aims to optimize the drug reimbursement system, enhancing both the efficiency of medical insurance funds and the accessibility of essential medications for the public [1] Group 1: Drug List Changes - The new drug list includes 114 new drugs, with 50 being innovative first-class drugs, while 29 drugs with lower clinical value have been removed, bringing the total to 3,253 drugs [1] - The updated list covers key areas such as oncology, rare diseases, chronic diseases, and pediatric medications [1] Group 2: New Drug Characteristics - Newly included drugs exhibit three significant characteristics: they either fill clinical treatment gaps, are superior alternatives, or offer better cost-effectiveness [1] - Specific examples include new drugs for treating triple-negative breast cancer and pancreatic cancer, which improve affordability and accessibility for patients [2] Group 3: Payment Scope Adjustments - The payment scope for 65 drugs has been revised to better align with clinical realities, such as expanding the use of certain drugs to a broader patient age range [3] - New conditions have been added for some drugs to prevent misuse while ensuring that medical insurance funds are utilized effectively [3] Group 4: Cost Reduction Initiatives - The combination of price negotiations and medical insurance reimbursements is expected to lower the cost of medications for the public [3] - A new "Commercial Health Insurance Innovative Drug List (2025)" has been introduced, including 19 high-value innovative drugs, which complements basic medical insurance and addresses diverse health needs [3] Group 5: Implementation and Accessibility - The medical insurance department has mandated that medical institutions incorporate newly added drugs into their procurement lists by the end of February [4] - A transition policy allows for a 6-month period during which patients can still purchase removed drugs at previous reimbursement rates [4] - A new feature for querying the updated basic medical insurance drug list has been launched on the National Medical Insurance Bureau's WeChat public account [4]

Core Insights - The latest medical insurance drug list will be implemented on January 1, 2026, featuring significant updates that focus on clinical needs and expand access to essential medications [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [1] - Notable new drugs include treatments for triple-negative breast cancer, pancreatic cancer, and long-acting growth hormone injections for children with growth deficiencies [3] Group 2: Expanded Payment Coverage - The payment coverage has been expanded for 65 drugs, with new indications included for existing medications, such as additional targets for non-small cell lung cancer treatments and broader age eligibility for rare disease treatments [4] - Adjustments have been made to payment criteria to better align with clinical practices, such as changing the payment range for certain drugs from "previous chemotherapy" to "past chemotherapy" [4] Group 3: Restrictions and Adjustments - New limitations have been introduced for certain drugs to prevent misuse, ensuring that insurance funds are utilized effectively [5] - Some drugs have had non-core restrictions removed, but the fundamental usage requirements remain unchanged, such as the diabetes medication semaglutide [5] Group 4: Drug List Structure and Transition Policies - The updated list has removed 29 drugs that are either clinically obsolete or have not been produced for an extended period, including several that did not successfully renew their negotiation agreements [6] - A transition policy has been established, allowing a 6-month period for patients to purchase removed drugs at previous reimbursement standards [6] - A new query function for the basic medical insurance directory has been launched on the National Medical Insurance Bureau's WeChat account for easier access to the updated list [6]

Core Insights - The latest medical insurance drug list will be implemented on January 1, 2026, featuring significant updates that benefit insured individuals [1][9]. Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [10]. - New drugs include treatments for critical conditions such as triple-negative breast cancer and pancreatic cancer, as well as medications for growth hormone deficiency in children and diabetes [12]. Group 2: Expanded Payment Coverage - The payment scope has been expanded for 65 drugs, with new indications included for several medications, such as additional targets for non-small cell lung cancer treatment and expanded age eligibility for narcolepsy treatment [4][12]. - Adjustments have been made to payment criteria to better align with clinical practices, such as changing the payment scope for certain drugs from "previous chemotherapy" to "past chemotherapy" [4][12]. Group 3: Drug Removals - A total of 29 drugs have been removed from the list, primarily those that have been clinically obsolete or not produced for an extended period [5][14]. - A transition policy has been established, allowing a 6-month period for insured individuals to purchase removed drugs at the original reimbursement standards [14]. Group 4: Accessibility and User Support - The National Medical Insurance Bureau has launched a new function on its WeChat public account for users to query the updated basic medical insurance directory [8][16].

Core Insights - The latest medical insurance drug list will be implemented on January 1, 2026, featuring significant updates that focus on clinical needs and patient benefits [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [1] - Notable new drugs include treatments for triple-negative breast cancer, pancreatic cancer, and long-acting growth hormone injections for children with growth deficiencies [3] Group 2: Expanded Payment Scope - The payment scope has been broadened to include 65 drugs with new indications, such as additional targets for non-small cell lung cancer and expanded age eligibility for narcolepsy treatment [4] - Adjustments have been made to payment criteria to better align with clinical practices, such as changing the eligibility for certain drugs from "previous chemotherapy" to "prior chemotherapy" [4] Group 3: Restrictions and Adjustments - New limitations have been introduced for certain drugs to prevent misuse, ensuring that insurance funds are utilized effectively [5] - Some drugs have had non-core restrictions removed, but the fundamental usage requirements remain unchanged, such as the diabetes medication semaglutide [5] Group 4: Drug Removal and Transition Policies - A total of 29 drugs have been removed from the list, primarily those that are clinically obsolete or no longer produced [6] - A transition period of six months has been established for patients to continue purchasing removed drugs at previous reimbursement standards [6] Group 5: Accessibility Features - The National Medical Insurance Bureau has launched a new feature on its WeChat account for users to query the updated basic medical insurance directory [6]